Question: Mutect2 "somatic" variants with resistant tissue culture lines
1
gravatar for shawn.w.foley
7 months ago by
shawn.w.foley1.1k
USA
shawn.w.foley1.1k wrote:

Hello!

I'm trying to establish an analysis pipeline for whole exome seq (WES) of a cancer cell line with acquired resistance. In this experiment we have our cell line grown under normal conditions (WT) and our cell line that has been grown under increasing concentrations of drug and has acquired drug resistance. With three replicates each, we performed WES, and I plan on using Mutect2 through GATK to compare these samples.

In my mind, it makes sense to treat the resistant sample as "Tumor" and the WT sample as "Normal" and call "somatic" mutations using Mutect2. I've read through the Mutect2 tutorial from GATK, and had a few thoughts. Essentially the pipeline is:

1) Create a panel of normals (PON).

2) Run Mutect2 to identify variants.

3) Run GetPileupSummaries and CalculateContamination to account for heterogeneity of tumor samples.

4) Run FilterMutectCalls with the output from (2) and (3).

My biggest question is the necessity of steps 3 and 4. I understand their utility if these were true tumor/normal biopsies, but we don't have any contaminating cell types in these samples, so calculating contamination and filtering based on that doesn't seem necessary. Am I missing something? Does it make sense to take the output of Mutect2 directly and use that as my list of differential mutations?

Thank you for the help!

ADD COMMENTlink modified 6 months ago by Biostar ♦♦ 20 • written 7 months ago by shawn.w.foley1.1k
1

Indeed, as the population is a 'pure' cell-line, no contamination should be expected. In practice, however, the cell-line will likely have become heterogeneous over time, and certainly more so in response to the drug. I would run with GetPileupSummaries and CalculateContamination to check their behaviour and then make a judgement call after that.

ADD REPLYlink written 6 months ago by Kevin Blighe51k
Please log in to add an answer.

Help
Access

Use of this site constitutes acceptance of our User Agreement and Privacy Policy.
Powered by Biostar version 2.3.0
Traffic: 1471 users visited in the last hour